BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 15257956)

  • 1. Strengths and weaknesses of established indirect models to detect recombinant human erythropoietin abuse on blood samples collected 48-hr post administration.
    Connes P; Caillaud C; Simar D; Villard S; Sicart MT; Audran M
    Haematologica; 2004 Jul; 89(7):891-2. PubMed ID: 15257956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-generation blood tests to detect erythropoietin abuse by athletes.
    Gore CJ; Parisotto R; Ashenden MJ; Stray-Gundersen J; Sharpe K; Hopkins W; Emslie KR; Howe C; Trout GJ; Kazlauskas R; Hahn AG
    Haematologica; 2003 Mar; 88(3):333-44. PubMed ID: 12651273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of human reticulocyte genes reveals altered erythropoiesis: potential use to detect recombinant human erythropoietin doping.
    Varlet-Marie E; Audran M; Lejeune M; Bonafoux B; Sicart MT; Marti J; Piquemal D; Commes T
    Haematologica; 2004 Aug; 89(8):991-7. PubMed ID: 15339684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of physical fitness and endurance exercise on indirect biomarkers of recombinant erythropoietin misuse.
    Abellan R; Ventura R; Pichini S; Palmi I; Bellver M; Olive R; Pacifici R; Pascual JA; Zuccaro P; Segura J
    Int J Sports Med; 2007 Jan; 28(1):9-15. PubMed ID: 16804802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of microdose recombinant human erythropoietin regimens in athletes.
    Ashenden M; Varlet-Marie E; Lasne F; Audran M
    Haematologica; 2006 Aug; 91(8):1143-4. PubMed ID: 16870547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis.
    Parisotto R; Wu M; Ashenden MJ; Emslie KR; Gore CJ; Howe C; Kazlauskas R; Sharpe K; Trout GJ; Xie M
    Haematologica; 2001 Feb; 86(2):128-37. PubMed ID: 11224480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of blood erythroid markers useful in revealing erythropoietin abuse in athletes.
    Magnani M; Corsi D; Bianchi M; Paiardini M; Galluzzi L; Gargiullo E; Parisi A; Pigozzi F
    Blood Cells Mol Dis; 2001; 27(3):559-71. PubMed ID: 11355895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of pre-competition and altitude training on blood models used to detect erythropoietin abuse by athletes.
    Ashenden MJ; Sharpe K; Schoch C; Schumacher YO
    Haematologica; 2004 Aug; 89(8):1019-20. PubMed ID: 15339692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Oxygen blood transport and doping].
    Audran M; Connes P; Varlet-Marie E
    Bull Acad Natl Med; 2003; 187(9):1669-79; discussion 1680-3. PubMed ID: 15369237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interpretation of secondary blood markers can get hazardous in case of a discontinuous rhEPO treatment.
    Robinson N; Saugy M; Buclin T; Gremion G; Mangin P
    Haematologica; 2002 Jun; 87(6):ELT28. PubMed ID: 12031936
    [No Abstract]   [Full Text] [Related]  

  • 11. Detection of recombinant human erythropoietin in urine for doping analysis: interpretation of isoelectric profiles by discriminant analysis.
    Lasne F; Thioulouse J; Martin L; de Ceaurriz J
    Electrophoresis; 2007 Jun; 28(12):1875-81. PubMed ID: 17503402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A peculiar pattern of expression of the transferrin receptor (CD71) by reticulocytes in patients given recombinant human erythropoietin (rHuEPO): a novel marker for abuse in sport?
    Borrione P; Parisi A; Salvo RA; Spaccamiglio A; Pautasso M; Baraban D; Piccoli GB; Pigozzi F; Angeli A
    J Biol Regul Homeost Agents; 2007; 21(3-4):79-88. PubMed ID: 18261259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of common hematologic abnormalities on the ability of blood models to detect erythropoietin abuse by athletes.
    Parisotto R; Ashenden MJ; Gore CJ; Sharpe K; Hopkins W; Hahn AG
    Haematologica; 2003 Aug; 88(8):931-40. PubMed ID: 12935982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrimination of recombinant and endogenous urinary erythropoietin by calculating relative mobility values from SDS gels.
    Kohler M; Ayotte C; Desharnais P; Flenker U; Lüdke S; Thevis M; Völker-Schänzer E; Schänzer W
    Int J Sports Med; 2008 Jan; 29(1):1-6. PubMed ID: 18050057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A third generation approach to detect erythropoietin abuse in athletes.
    Sharpe K; Ashenden MJ; Schumacher YO
    Haematologica; 2006 Mar; 91(3):356-63. PubMed ID: 16503554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doping in the recombinant era: strategies and counterstrategies.
    Azzazy HM; Mansour MM; Christenson RH
    Clin Biochem; 2005 Nov; 38(11):959-65. PubMed ID: 16286094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Genetic Doping" with erythropoietin cDNA in primate muscle is detectable.
    Lasne F; Martin L; de Ceaurriz J; Larcher T; Moullier P; Chenuaud P
    Mol Ther; 2004 Sep; 10(3):409-10. PubMed ID: 15336641
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of exercise on the isoelectric patterns of erythropoietin.
    Lamon S; Martin L; Robinson N; Saugy M; Ceaurriz Jd; Lasne F
    Clin J Sport Med; 2009 Jul; 19(4):311-5. PubMed ID: 19638826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rogue athletes and recombinant DNA technology: challenges for doping control.
    Azzazy HM; Mansour MM
    Analyst; 2007 Oct; 132(10):951-7. PubMed ID: 17893796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applications and biomonitoring issues of recombinant erythropoietins for doping control.
    Tsitsimpikou C; Kouretas D; Tsarouhas K; Fitch K; Spandidos DA; Tsatsakis A
    Ther Drug Monit; 2011 Feb; 33(1):3-13. PubMed ID: 21099742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.